Interview: Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage…
Established in 1977, Entod has always shown a strong commitment to Innovation & Quality in Ophthalmic, ENT and Paediatric medicines. Our commitment and dedication to consistently achieve the HIGHEST QUALITY INTERNATIONAL STANDARDS has won us the trust of many in the ophthalmic, ENT and respiratory fraternity.
Entod has been committed in collaborating with various medical fraternities in support of educational and professional development programmes and conferences. We want to make a real difference to medical practice and to the quality of medical care received by patients.
We incorporate the latest TECHNOLOGIES in pharmaceutical manufacturing and are proud that our products are manufactured at state-of-the-art internationally approved manufacturing facilities.
Entod is continually expanding its innovative product range, rapidly developing its R&D facilities and growing its sales field force globally. With several exciting new products, research projects and clinical initiatives in the pipeline, Entod´s global image is taking good shape.
Contact:
Address: Ashirwad building, S.V.Road, Opp. Badi Masjid, Bandra(W), Mumbai-400050 INDIA
Website: entodpharma.com
Email: feedback@entodpharma.com
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage…
You have already publicly announced that, despite being late in India, Lonza has been increasingly looking into expanding in the Indian market. First of all, what do you think sparked…
Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group,…
To start off, can you tell us how you have seen the pharmaceutical industry developing in India? Has the perception of India by big pharma changed over the years? First…
A catalyst of India’s shifting industry dynamics has been the sector’s M&A activity. We already saw majors such as Piramal going to Abbott and Ranbaxy to Daiichi-Sankyo… And while Andrew…
With the recent event “Vibrant Gujarat”, the state of Gujarat aimed to showcase the region’s opportunities and advanced infrastructure, hosting 1,400 delegates from 101 countries as well as several presentations…
You founded Calyx in 1979 with a three-person team. At the time, you were just 21 years old! What was the vision behind the creation of the company? Essentially, the…
Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it…
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Our last report on India dates back to 2006, right after the Patent Law was passed. What developments have you seen happening in the industry since then? There has been…
See our Cookie Privacy Policy Here
